Literature DB >> 16705723

Can axillary dissection be avoided in patients with sentinel lymph node metastasis?

Angela Katz1, Andrzej Niemierko, Irene Gage, Sheila Evans, Margaret Shaffer, Thomas Fleury, Frederick P Smith, Peter E Petrucci, Richard Flax, Cynthia Drogula, Colette Magnant.   

Abstract

BACKGROUND: Who should undergo a completion dissection following identification of a +sentinel lymph node (SLN) is controversial.
METHODS: The records of 1,133 patients who underwent SLN mapping were reviewed. The association between patient, tumor, and treatment characteristics and the presence of +SLNs and +nonSLNs was analyzed using two-way tables of frequency counts and Pearson chi2 test. Possible predictors of +SLNs and +nonSLNs were analyzed using simple and multiple logistic regression.
RESULTS: One thousand one hundred forty-eight SLN procedures were performed. 367 procedures (32%) yielded +SLNs. For patients with a +SLN, on multiple logistic regression analysis LVSI, increasing numbers of +SLNs, decreasing numbers of negative SLNs, and increasing size of the largest SLN metastasis were statistically significantly associated with increased likelihood of nonSLN involvement. No subgroup was identified that did not have a significant rate of nonSLN involvement on completion axillary dissection, except those who had a large number of negative SLNs (> or =3) and small size of the largest SLN metastasis (<10 mm).
CONCLUSIONS: A definitive answer to the question of who needs a completion axillary dissection awaits the results of ongoing trials. In the interim, our data does not support eliminating dissection for any subgroup of patients with +SLNs. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705723     DOI: 10.1002/jso.20514

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays.

Authors:  Georg Sauer; Nicole Schneiderhan-Marra; Rainer Muche; Karin Koretz; Cornelia Kazmaier; Rolf Kreienberg; Thomas Joos; Helmut Deissler
Journal:  J Cancer Res Clin Oncol       Date:  2011-04-24       Impact factor: 4.553

Review 2.  Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Arch Pathol Lab Med       Date:  2016-08       Impact factor: 5.534

3.  Factors that determine whether a patient receives completion axillary lymph node dissection after a positive sentinel lymph node biopsy for breast cancer in British Columbia.

Authors:  Nava Aslani; Todd Swanson; Hagen Kennecke; Ryan Woods; Noelle Davis
Journal:  Can J Surg       Date:  2011-08       Impact factor: 2.089

Review 4.  Sentinel lymph nodes for breast carcinoma: an update on current practice.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.